ATXS
Astria Therapeutics Inc

11,118
Loading...
Loading...
News
all
press releases
All You Need to Know About Astria Therapeutics (ATXS) Rating Upgrade to Buy
Astria Therapeutics (ATXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·1d ago
News Placeholder
More News
News Placeholder
Wall Street Analysts Believe Astria Therapeutics (ATXS) Could Rally 294.75%: Here's is How to Trade
The consensus price target hints at a 294.8% upside potential for Astria Therapeutics (ATXS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·3d ago
News Placeholder
Astria Therapeutics, Inc. (ATXS) Now Trades Above Golden Cross: Time to Buy?
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Zacks·4d ago
News Placeholder
Does Astria Therapeutics (ATXS) Have the Potential to Rally 333.88% as Wall Street Analysts Expect?
The mean of analysts' price targets for Astria Therapeutics (ATXS) points to a 333.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·28d ago
News Placeholder
Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D...
Business Wire·7mo ago
News Placeholder
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three...
Business Wire·7mo ago
News Placeholder
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 16,500...
Business Wire·7mo ago
News Placeholder
Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D...
Business Wire·7mo ago
News Placeholder
Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session
Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present quality...
Business Wire·7mo ago
News Placeholder
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced initiation of a Phase 1a...
Business Wire·8mo ago

Latest ATXS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.